Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 5, 2024
Reporting Period: Second Quarter ended June 30, 2024
This filing announces the financial results for the second quarter of 2024. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text serves as a cover report and does not contain specific numerical data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced Exhibit 99.1 press release.
Material Changes
The filing text does not provide a clear value or description of material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. This information is expected to be detailed in the referenced Exhibit 99.1 press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 5, 2024) for specific Q2 2024 revenue and net income figures.
- Verify year-over-year growth rates and margin trends in the attached press release.
- Check for any updates to full-year 2024 financial guidance provided in the press release.
- Confirm the status of key product launches or regulatory approvals mentioned in the detailed results.